Monitor the company's daily trading volume and any subsequent 8-K or prospectus supplement filings for actual share sales under the ATM program. The large authorized amount ($100M vs $153M market cap) creates persistent overhang; any material volume of sales would likely pressure the stock price.
Price Chart
Executive Summary
Indaptus Therapeutics entered into an amended and restated at-the-market offering agreement with H.C. Wainwright, enabling the sale of up to $100 million in common stock. This filing, combined with the prospectus supplement filed the prior day, formalizes a significant capital raise capacity for the clinical-stage biotech. The potential for substantial dilution overhangs the stock, though the company has no obligation to sell any shares.
Key Facts
- Indaptus entered into an Amended and Restated At the Market Offering Agreement with H.C. Wainwright for up to $100,000,000 in common stock.
- The agreement amends and restates the prior June 1, 2022 agreement.
- H.C. Wainwright will receive a 3.0% placement fee on shares sold as agent.
- The company filed a related prospectus supplement on August 31, 2026.
- As of August 26, 2026, the last reported sale price was $1.14 per share.
- Prior sales under the original agreement totaled approximately $2.74 million (520,000 shares at ~$2.34M and 5,428 shares at ~$0.4M).
Financial Impact
Up to $100,000,000 in potential common stock sales, creating significant dilution risk for existing shareholders.
Risk Factors
- Significant dilution if the full $100 million ATM is utilized.
- Stock price pressure from continuous selling into the market.
- Clinical-stage biotech with no approved products, making equity financing a primary capital source.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-040926 |
| Exhibit: ex5-1.htm | 0001493152-26-040926 |
| Document: form8-k.htm | 0001493152-26-040926 |
| Document: 0001493152-26-040926-index-headers.html | 0001493152-26-040926 |
| Document: 0001493152-26-040926-index.html | 0001493152-26-040926 |
| Document: 0001493152-26-040926.txt | 0001493152-26-040926 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | 8-K | $2.56 $3.93 | ▼ −53.52% | ▼ −52.89% | $2.33 (+8.98%) |
Sep 4, 2026 27d ago | 424B5 | $1.85 $3.64 | ▼ −96.76% | ▼ −97.88% | $2.33 (−25.95%) |
Sep 1, 2026 4w ago | 8-K | $1.13 $2.08 | ▼ −84.07% | ▼ −83.99% | $2.33 (−106.19%) |
Aug 26, 2026 5w ago | EFFECT | $1.14 $1.17 | ▼ −2.63% | ▼ −2.75% | $2.33 (−104.39%) |
Aug 17, 2026 6w ago | S-3 | $0.9361 $1.10 | ▼ −16.97% | ▼ −17.18% | $2.33 (−148.91%) |
Aug 13, 2026 7w ago | 8-K | $1.06 $1.38 | ▲ +30.19% | ▲ +32.15% | $2.33 (+119.81%) |
Jul 20, 2026 10w ago | EFFECT | $2.46 $2.61 | ▼ −6.10% | ▼ −6.52% | $2.33 (+5.28%) |
Jun 26, 2026 13w ago | S-3 | $3.06 $2.85 | ▲ +6.86% | ▲ +8.25% | $2.33 (+23.86%) |
Jun 24, 2026 14w ago | 8-K | $3.26 $2.94 | ▲ +9.82% | ▲ +11.38% | $2.33 (+28.53%) |
May 15, 2026 20w ago | 8-K | $1.59 $1.22 | ▲ +23.27% | ▲ +24.23% | $2.33 (−46.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access